Adrenogenital syndrome
diseaseOn this page
Also known as adrenogenital disorderandrogenital syndromecongenital adrenal hyperplasia
Summary
Adrenogenital syndrome (MONDO:0015898) is a disease and 70 clinical trials. Top therapeutic interventions include crinecerfont, fludrocortisone acetate, and hydrocortisone. A subtype of adrenal gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 70
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adrenogenital syndrome |
| Mondo ID | MONDO:0015898 |
| MeSH | D047808 |
| Orphanet | 181412 |
| ICD-11 | 131153029 |
| SNOMED CT | 267395000 |
| UMLS | C0302280 |
| MedGen | 86215 |
| GARD | 0020226 |
| MedDRA | 10061630 |
| Is cancer (heuristic) | no |
Also known as: adrenogenital disorder · adrenogenital syndrome · androgenital syndrome · congenital adrenal hyperplasia
Disease family
This is a subtype of adrenal gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › adrenal gland disorder › adrenogenital syndrome
Related subtypes (17): medulloadrenal hyperfunction, adrenal cortex disorder, adrenal medullary hyperplasia, pituitary dwarfism, pseudoleprechaunism syndrome, Patterson type, apparent mineralocorticoid excess, autoimmune polyendocrine syndrome type 1, adrenomyodystrophy, corticosteroid-binding globulin deficiency, Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency, hypoaldosteronism disease, primary pigmented nodular adrenocortical disease, adrenoleukodystrophy, adrenal gland neoplasm, ectopic ACTH secretion syndrome, endogenous Cushing syndrome, isolated micronodular adrenocortical disease
Subtypes (4): cortisone reductase deficiency, glucocorticoid resistance, congenital adrenal hyperplasia, acquired adrenogenital syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Fludrocortisone Acetate | Approved (phase 4) |
Clinical trials & evidence
Clinical trials
Clinical trials: 70.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 34 |
| PHASE2 | 14 |
| PHASE3 | 9 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03760835 | PHASE4 | RECRUITING | Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment |
| NCT04536662 | PHASE4 | UNKNOWN | Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency |
| NCT04490915 | PHASE3 | ACTIVE_NOT_RECRUITING | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia |
| NCT04806451 | PHASE3 | ACTIVE_NOT_RECRUITING | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) |
| NCT07144163 | PHASE3 | RECRUITING | A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia |
| NCT07159841 | PHASE2/PHASE3 | RECRUITING | A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) |
| NCT00001521 | PHASE3 | COMPLETED | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia |
| NCT02552251 | PHASE2/PHASE3 | UNKNOWN | COrticosteroid in Congenital Adrenal Hyperplasia |
| NCT02716818 | PHASE3 | COMPLETED | Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia |
| NCT03062280 | PHASE3 | COMPLETED | A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH |
| NCT03532022 | PHASE3 | WITHDRAWN | Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy |
| NCT05063994 | PHASE3 | COMPLETED | Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia |
| NCT05299554 | PHASE3 | COMPLETED | Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia |
| NCT04783181 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) |
| NCT05669950 | PHASE1/PHASE2 | RECRUITING | A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia |
| NCT06712823 | PHASE2 | RECRUITING | An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 |
| NCT07187375 | PHASE2 | RECRUITING | Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old |
| NCT07536269 | PHASE2 | NOT_YET_RECRUITING | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old |
| NCT00000102 | PHASE1/PHASE2 | COMPLETED | Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets |
| NCT00519818 | PHASE1/PHASE2 | COMPLETED | Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia |
| NCT01735617 | PHASE2 | COMPLETED | Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH |
| NCT01859312 | PHASE2 | COMPLETED | Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia |
| NCT02804178 | PHASE2 | COMPLETED | A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia |
| NCT03257462 | PHASE2 | COMPLETED | Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia |
| NCT03548246 | PHASE2 | WITHDRAWN | Androgen Reduction in Congenital Adrenal Hyperplasia |
| NCT03669549 | PHASE2 | TERMINATED | Nevanimibe HCl for the Treatment of Classic CAH |
| NCT03687242 | PHASE2 | COMPLETED | Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia |
| NCT04457336 | PHASE2 | TERMINATED | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH |
| NCT04544410 | PHASE2 | TERMINATED | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH |
| NCT05128942 | PHASE2 | TERMINATED | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH |
| NCT05907291 | PHASE2 | COMPLETED | Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) |
| NCT02349503 | PHASE1 | WITHDRAWN | Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia |
| NCT02574910 | PHASE1 | TERMINATED | Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 |
| NCT03019614 | PHASE1 | COMPLETED | An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone |
| NCT03051893 | PHASE1 | COMPLETED | A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations |
| NCT03718234 | PHASE1 | COMPLETED | Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia |
| NCT00250159 | Not specified | RECRUITING | Natural History Study of Patients With Excess Androgen |
| NCT04252001 | Not specified | NOT_YET_RECRUITING | Growing up With the Young Endocrine Support System (YESS!) |
| NCT04463316 | Not specified | RECRUITING | GROWing Up With Rare GENEtic Syndromes |
| NCT06564220 | Not specified | NOT_YET_RECRUITING | Testicular Adrenal Rest Tumor in Congenital Adrenal Hyperplasia Patients Attending Assuit University Children Hospital |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CRINECERFONT | 4 | 4 |
| FLUDROCORTISONE ACETATE | 4 | 2 |
| HYDROCORTISONE | 4 | 2 |
| HYDROCORTISONE CYPIONATE | 4 | 2 |
| CORTISONE ACETATE | 4 | 1 |
| FLUTAMIDE | 4 | 1 |
| LETROZOLE | 4 | 1 |
| NIFEDIPINE | 4 | 1 |
| PREDNISOLONE | 4 | 1 |
| PREDNISONE | 4 | 1 |
| TESTOLACTONE | 4 | 1 |
| TILDACERFONT | 2 | 5 |
| ATUMELNANT | 2 | 4 |
| NEVANIMIBE | 2 | 3 |
| FLUDROCORTISONE | 2 | 2 |
| VERUCERFONT | 2 | 1 |
| CHEMBL4740452 | 0 | 2 |
| CHEMBL15720 | 0 | 1 |
| CHEMBL166839 | 0 | 1 |
| CHEMBL4759307 | 0 | 1 |